Jena, Germany | 9 March 2020 | Carl Zeiss Meditec AG
- Jim Mazzo, current President of Ophthalmic Devices and Head of Ophthalmic Devices Strategic Business Unit for ZEISS will retire from ZEISS effective 1 May 2020 and will continue to support ZEISS as an advisor
- Dr. Euan Thomson will assume the role of Head of Ophthalmic Devices Strategic Business Unit for ZEISS and will be appointed President of Ophthalmic Devices
- Andrew Chang will be appointed as President of Carl Zeiss Meditec, Inc. He will continue to lead the global ophthalmic sales organization
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of €1,459.3m in fiscal year 2018/19 (as of 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.
For further information visit: www.zeiss.com/med